illumina provides services to dna testing company 23 and me.'s talk about this for just a moment before we get into the 23 and me news. what do you guys make of all of this >> i mean, i think in terms of 23 and me, it's not too surprising, right? because you do get to a point of saturation with these direct to consumer opportunities where people really do this once, maybe twice if they feel like they did it a long time ago and the technology is better they need to do it again. and it isn't a market for everybody. not everybody wants their data on the internet about their family history >> not even everybody wants to know whether they are going to test positive for the braca gene or whatever. some people choose not to know that >> the other part of the story is that 23 and me is not the leader in this category. that would be ancestry and -- now, 23 and me has done about 10 million dna tests to this point over a number of years. ancestry's been in the market for about six years and they've already done about 20 to 25 million and they are growing

. >> steve >> i'm going with illumina the price target that the analysts put out there is only 5% lower've got more than 5% risk in any other day my own so i don't think it's a near-term trade. it could best near term, though. >> doubling down, so to speak some. >> i bought some after the close, i bought it twice this morning. so if i was stupid before, now i'm a real moron [ laughter ] >> all right, jim lebenthal, what have you got? >> a lot of things are breaking out here boeing comes to mind, though because it seems like every weekend for the past three or four weeks, there's been some bad news that the stock just shrugs off, whether it's a micro processor needs to be replaced or an order got canceled frankly we're at the point with this name where you should start seeing good names. at some point the 737 max gets back in the air. the but the way this stock shrugs off >> but the headline risk >> the stock is just blowing past it. that's the point i'm trying to make you can cut your exposure. i don't own enough of it, but my waiting for it to come back to 341, i don't think it's going

illumina, shares are on pace for their worst day in nearly three years, falling 16% at this hour. you can see it's well off certainly the three-year lows but today, it is not a good picture. the firm cut its full year revenue forecast to 6%. that is a huge drop from the prior expectation of growth of 14%. if you don't know, illumina makes machines that fuel the current boom in personal genome sequencing and is blaming weakness in the direct-to-consumer market. the stock up 21% year-to-date and we are already more than halfway through the year. at the moment, a $57 clip on the stock brings it to $305.77. let's look at another health care stock taking a hit. widely held johnson & johnson. bloomberg reporting the justice department is investigating allegations that the company lied about the possible cancer risks of its talcum powder, baby powder. right now, that stock is down 4.66%. the consumer products maker which also makes as you know, tylenol, aveno, faces more than 13,000 talcum related lawsuits. j & j has denied allegations that its baby powder causes cancer. >>> happening so

the top of the empire state building in new york let's get a check on the stocks today shares of illumina are sliding after they cut revenue outlook for the second quarter blaming problems in it's direct to consumer business and lower sales of some products it's reducing it's revenue forecast for the year. look at that, shares down 10% for three months 16% today. daimler issuing a product warning. it expects to swing to a loss in the second quarter citing higher costs relating to the global recall of takata air bags shares down by more than a percent at this point but 18% in three months and shareholders will vote on the planned $38 billion share in august. it's expected shareholders will approve that deal but the price angered several investors saying carl icahn that called for a special board meeting. straight ahead, anyone listening? google claimed defense after new outrage services over it's google home assistant. you'll want to hear this story then a dramatic drug bust. incredible video you havtoe see. this is the teaser here. worldwide exchange is back after this dear tech, let's ta

. >> all right weiss, you first i wi illumina up 16%. do you still own it? >> i do. look, right now, bios is the key, i would say the key, it's important. that's been referred to european commissioner because of antitrust. but i think it passes. i think they make the acquisition. and there's no real competitor in the space so i love the stock. >> home depot, up 9% since, stay with it? >> definitely. home depot is one of the few retailers that people actually like to go to. they have the whole contractor business with the housing stock in america having aged and appreciated, it means more renovations, more improvement. we think that there's many years of double digit growth ahead >> joey, mckesson, 19% >> i'm staying with it i think steven was with me on this as well health care provided an opportunity. you had the chance when you had the selloff related to the political issues issues in wash, stay with it though. >> well, of course some of the picks haven't quite worked out just yet. >> i got to go >> xpi still like bio tech, eve though i own some individual ones, i'

standout leading up nearly 2% on the day and over 3% for the week and the worst performer, i wi illumina the sector off 3.5% especially after the concerns about tougher drug pricing controls potentially coming from the white house. >> and we'll turn now to johnson & johnson plunging on new fallout surrounding its baby powder controversy meg tirrell has more >> they are facing thousands of lawsuits claiming its talc products are linked to cancer and today it is reported that the justice department is pursuing a criminal investigation. for its part j & j says that the implication that there is a new development is wrong noting that it disclosed a subpoena from the justice department in february and disputed claims that its products cause cancer. and closing arguments are scheduled monday in a case that the company contributed to the opoid crisis >> and charlie, have you got a specific view on j & j >> jaw, yeah, and nothing new happened today the idea that they are looking into fraud is not significant news, not that would take it down tens of millions like it did. and we don't see that th